These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 10473027)

  • 1. Group sequential procedures for repeated events data with frailty.
    Jiang W
    J Biopharm Stat; 1999 Aug; 9(3):379-99. PubMed ID: 10473027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multivariate tests of means in independent groups designs. Effects of covariance heterogeneity and nonnormality.
    Lix LM; Keselman HJ
    Eval Health Prof; 2004 Mar; 27(1):45-69. PubMed ID: 14994559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Poisson regression analysis in clinical research.
    Kianifard F; Gallo PP
    J Biopharm Stat; 1995 Mar; 5(1):115-29. PubMed ID: 7613557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficient group sequential designs when there are several effect sizes under consideration.
    Jennison C; Turnbull BW
    Stat Med; 2006 Mar; 25(6):917-32. PubMed ID: 16220524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparing methods for calculating confidence intervals for vaccine efficacy.
    Ewell M
    Stat Med; 1996 Nov 15-30; 15(21-22):2379-92. PubMed ID: 8931208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sample sizes for experiments with multivariate repeated measures.
    Guo X; Johnson WD
    J Biopharm Stat; 1996 May; 6(2):155-76. PubMed ID: 8732911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of retinyl acetate and melatonin on N-methyl-N-nitrosourea-induced mammary carcinogenesis in rats. A preliminary report.
    Bojková B; Kubatka P; Môciková K; Mníchová M; Ahlersová E; Ahlers I
    Folia Biol (Praha); 2000; 46(2):73-6. PubMed ID: 10813094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal number of repeated measures and group sizes in clinical trials with linearly divergent treatment effects.
    Winkens B; Schouten HJ; van Breukelen GJ; Berger MP
    Contemp Clin Trials; 2006 Feb; 27(1):57-69. PubMed ID: 16260188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sample size estimation for GEE method for comparing slopes in repeated measurements data.
    Jung SH; Ahn C
    Stat Med; 2003 Apr; 22(8):1305-15. PubMed ID: 12687656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bayesian inference for recurrent events data using time-dependent frailty.
    Manda SO; Meyer R
    Stat Med; 2005 Apr; 24(8):1263-74. PubMed ID: 15568192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A practical limit to trials needed in one-person randomized controlled experiments.
    Alemi R; Alemi F
    Qual Manag Health Care; 2007; 16(2):130-4. PubMed ID: 17426611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two-stage design of clinical trials involving recurrent events.
    Cook RJ; Bergeron PJ; Boher JM; Liu Y
    Stat Med; 2009 Sep; 28(21):2617-38. PubMed ID: 19579215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Robust tests for treatment comparisons based on recurrent event responses.
    Cook RJ; Lawless JF; Nadeau C
    Biometrics; 1996 Jun; 52(2):557-71. PubMed ID: 8672703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-parametric methods for comparing multiple treatment groups to a control group, based on incomplete non-decreasing repeated measurements.
    Davis CS
    Stat Med; 1996 Dec; 15(23):2509-21. PubMed ID: 8961460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The analysis of cancer chemoprevention experiments.
    Kokoska SM
    Biometrics; 1987 Sep; 43(3):525-34. PubMed ID: 3663816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of a within-subject design with covariates.
    Patel HI
    J Biopharm Stat; 1997 Jul; 7(3):369-81. PubMed ID: 9252831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The statistical analysis of cancer inhibition/promotion experiments.
    Kokoska SM; Hardin JM; Grubbs CJ; Hsu C
    Anticancer Res; 1993; 13(5A):1357-63. PubMed ID: 8239506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selecting the best treatment in designed experiments.
    Polansky AM
    Stat Med; 2003 Nov; 22(22):3461-71. PubMed ID: 14601013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficient ways exist to obtain the optimal sample size in clinical trials in rare diseases.
    van der Lee JH; Wesseling J; Tanck MW; Offringa M
    J Clin Epidemiol; 2008 Apr; 61(4):324-30. PubMed ID: 18313556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Power and sample size computations in simultaneous tests for non-inferiority based on relative margins.
    Dilba G; Bretz F; Hothorn LA; Guiard V
    Stat Med; 2006 Apr; 25(7):1131-47. PubMed ID: 16217842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.